FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
The endorsement follows overwhelming support for the share swap preceding the merger,
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The first of four planned modules at the new plant is expected to come online by summer 2026
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Subscribe To Our Newsletter & Stay Updated
